Moderna's influenza vaccine candidate uses conventional mRNA technology that was leveraged successfully during the COVID-19 response, resulting in one of the first two FDA-authorized - and ...
Moderna MRNA-2.31%decrease ... Human Services Department to accelerate the development of its bird influenza vaccine as concerns grow about a bird flu pandemic in humans. The financial package ...
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, alongside other influenza vaccines, health ...
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as concerns about a bird flu pandemic in ...
Moderna plans to advance research on the mRNA vaccine into a phase 3 trial after receiving positive results in earlier phases, which it plans to present at a scientific conference in the near future.
In 2023, Moderna initiated a phase 1/2 study to generate safety and immunogenicity data of the shot in healthy adults ages 18 and older. The trial included vaccine candidates against two avian ...